Eli Lilly and Company (LLY) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Eli Lilly and Company and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 2, 2026. Differences are shown without an overall score or investment verdict.
LLY
Eli Lilly and Company
$1,148.84HealthcareAt close: Jul 31, 2026, 4:00 PM ET
NVO
Novo Nordisk A/S
$47.08HealthcareAt close: Jul 31, 2026, 4:00 PM ET
Total return — LLY vs NVO
growth of $100 · dividends reinvested · last 30yLLY +8293.5%NVO +10806.6%NVO compounded faster
LLY NVO
LLY vs NVO: by the numbers
- •LLY is the larger company ($1.08T vs $209.19B market cap).
- •NVO trades at the lower trailing earnings multiple (11.01 vs 40.81 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (37.14% vs 34.98% net margin).
- •LLY grew revenue faster over the past five years (23.17% vs 20.73% CAGR).
- •NVO pays the higher dividend yield (3.83% vs 0.56%).
Metrics side by side
Valuation
| Metric | LLY | NVO |
|---|---|---|
| P/E ratio | 40.81 | 11.01 |
| Forward P/E | 32.79 | N/A |
| P/S ratio | 14.25 | 4.09 |
| P/B ratio | 32.99 | 6.69 |
| PEG ratio | 0.49 | 8.16 |
| EV / EBITDA | 30.72 | 8.62 |
| FCF yield | 1.32% | 2.31% |
Profitability
| Metric | LLY | NVO |
|---|---|---|
| Gross margin | 83.51% | 81.83% |
| Operating margin | 45.87% | 45.21% |
| Net margin | 34.98% | 37.14% |
| ROE | 81.01% | 60.74% |
| ROIC | 30.20% | 29.53% |
Dividends
| Metric | LLY | NVO |
|---|---|---|
| Dividend yield | 0.56% | 3.83% |
| Payout ratio | 28.09% | 49.80% |
Growth (annualized)
| Metric | LLY | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 23.17% | 20.73% |
| EPS CAGR (5Y) | 28.88% | 19.59% |
| FCF CAGR (5Y) | 19.54% | -5.86% |
| Total return CAGR (5Y) | 37.65% | 2.46% |
Frequently asked
- Which has the lower trailing P/E, LLY or NVO?
- NVO has the lower trailing P/E: LLY trades at 40.81 and NVO at 11.01. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, LLY or NVO?
- Over the past five years, LLY grew revenue faster — LLY at a 23.17% CAGR versus NVO at 20.73%.
- Does LLY or NVO pay a bigger dividend?
- LLY yields 0.56% and NVO yields 3.83% based on trailing dividends and the latest price.
- Is LLY or NVO more profitable?
- NVO runs the higher net margin — LLY at 34.98% versus NVO at 37.14%.
- How have LLY and NVO total returns compared?
- Over the past 10 years, LLY delivered 32.17% and NVO delivered 7.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Eli Lilly and P/E ratioNovo Nordisk A/S P/E ratioEli Lilly and dividend yieldNovo Nordisk A/S dividend yieldEli Lilly and ROENovo Nordisk A/S ROEEli Lilly and operating marginNovo Nordisk A/S operating marginEli Lilly and revenue growthNovo Nordisk A/S revenue growthEli Lilly and free cash flowNovo Nordisk A/S free cash flow
Eli Lilly and & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 2, 2026.